TY - JOUR
T1 - Exogenous melatonin as a treatment for secondary sleep disorders
T2 - A systematic review and meta-analysis
AU - Li, Tian
AU - Jiang, Shuai
AU - Han, Mengzhen
AU - Yang, Zhi
AU - Lv, Jianjun
AU - Deng, Chao
AU - Reiter, Russel J.
AU - Yang, Yang
N1 - Funding Information:
This work was supported by the National Natural Science Foundation of China ( 81500263 and 81673578 ) and China Postdoctoral Science Foundation ( 2016T90973 and 2015M572681 ). We are indebted to the authors of the primary studies. Furthermore, we sincerely appreciate the hard work from the distinguished editors and reviewers.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/1
Y1 - 2019/1
N2 - Melatonin is a physiological indoleamine involved in circadian rhythm regulation and it is currently used for secondary sleep disorders supported by empirical evidence. A small amount of evidence and some controversial results have been obtained in some randomized controlled trials (RCT). The objective of this meta-analysis is to determine the efficacy of exogenous melatonin versus placebo in managing secondary sleep disorders. Literature retrieval of eligible RCT was performed in 5 databases (PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and Web of Science). In total, 7 studies of 205 patients were included. Pooled data demonstrate that exogenous melatonin lowers sleep onset latency and increases total sleep time, whereas it has little if any effect on sleep efficiency. Although, the efficacy of melatonin still requires further confirmation, this meta-analysis clearly supports the use of melatonin as a management for patients with secondary sleep disorders.
AB - Melatonin is a physiological indoleamine involved in circadian rhythm regulation and it is currently used for secondary sleep disorders supported by empirical evidence. A small amount of evidence and some controversial results have been obtained in some randomized controlled trials (RCT). The objective of this meta-analysis is to determine the efficacy of exogenous melatonin versus placebo in managing secondary sleep disorders. Literature retrieval of eligible RCT was performed in 5 databases (PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and Web of Science). In total, 7 studies of 205 patients were included. Pooled data demonstrate that exogenous melatonin lowers sleep onset latency and increases total sleep time, whereas it has little if any effect on sleep efficiency. Although, the efficacy of melatonin still requires further confirmation, this meta-analysis clearly supports the use of melatonin as a management for patients with secondary sleep disorders.
KW - Melatonin
KW - Meta-analysis
KW - Secondary sleep disorders
KW - Sleep efficiency
KW - Sleep onset latency
KW - Total sleep time
UR - http://www.scopus.com/inward/record.url?scp=85048719132&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048719132&partnerID=8YFLogxK
U2 - 10.1016/j.yfrne.2018.06.004
DO - 10.1016/j.yfrne.2018.06.004
M3 - Review article
C2 - 29908879
AN - SCOPUS:85048719132
VL - 52
SP - 22
EP - 28
JO - Frontiers in Neuroendocrinology
JF - Frontiers in Neuroendocrinology
SN - 0091-3022
ER -